Drug intelligence / Profile preview

CNI-Resistant CAR-Tregs v2.2

Development stage: Preclinical
Lead developer: Regatta Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

CNI-Resistant CAR-Tregs v2.2 is an investigational genetically engineered regulatory T cell (Treg) therapy developed by Regatta Bio (formerly Regatta Medical) for the treatment of transplantation-related conditions and autoimmune disorders. The therapy utilizes a proprietary platform to engineer Tregs that are resistant to suppression by calcineurin inhibitors (CNIs), such as tacrolimus and cyclosporine, which are standard-of-care immunosuppressants used after organ transplantation. This modification allows the therapeutic Tregs to maintain their suppressive function and persist in the presence of systemic immunosuppression. Additionally, the cells are engineered for IL-2 independence to enhance survival and persistence without exogenous IL-2 and express a chimeric antigen receptor (CAR) targeting OX40 ligand (OX40L) to improve antigen specificity and control alloreactivity.

Other names: calcineurin inhibitor-resistant CAR-TregCNI-resistant chimeric antigen receptor regulatory T cellscalcineurin inhibitor-resistant chimeric antigen receptor regulatory T cellsEngineered OX40L CAR-Tregs

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on CNI-Resistant CAR-Tregs v2.2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNI-Resistant CAR-Tregs v2.2.

Explore the full profile